Latest News

Sanofi invests €170m to expand flu jab facility

Vaccine production in Sanofi's sole production site in France started in 1973. © Sanofi Pasteur


by tg

Sanofi is investing €170m to expand its vaccine manufacturing site in Val de Reuil, France, which produces 900 million vaccine doses worldwide each year.

The new facility will allow Sanofi Pasteur, the vaccines business unit of Sanofi, to expand supply of VaxigripTetra. The quadrivalent influenza vaccine contains two A strains (A/H1N1 and A/H3N2) and two B strains (B/Victoria and B/Yamagata) of influenza virus, as recommended by the World Health Organization. The jab is indicated for adults and children from 3 years and older

Sanofi plans to complete the expansion by 2021, and will begin producing vaccines in the new facility in 2022.  The investment adds to other major capital expenditures Sanofi has made in recent years to improve and expand its vaccine production capacities across France, the United States and Mexico.

Four new autoantigens trigger multiple sclerosis

Despite considerable progress in the treatment of multiplesclerosis (MS), the disease still often leads to permanent neurological disability....

Orphan drug developer Minoryx raises €51m

The Series C round was co-led by Columbus Venture Partners and Caixa Capital Risc, and supported by CDTI Innvierte, Fund+, Ysios Capital and other...

Evotec and BMS intensify R&D on protein degraders

Novo Holdings co-leads €40m Qure.ai financing

Qure.ai said it will use the proceeds from the $40m financing round to intesify product development for  critical care and community...

AXA launches €440 m private equity healthcare strategy

The Strategy focuses specifically on companies in four core areas: medical devices, biopharmaceuticals, vaccines, and diagnostics. The...

Commission to establish EU health data space

The EU Commission is set to present a draft law on a "European health data area" this Tuesday, which could be a big thing for digital...

Avantium gets EU grant

Avantium said it will use the EU grant from the Horizon Europe programme for its participation in the 4-year research and development programme...